GlassScriptPhysician profile
Michael Andre Liss
NPI 1477733012
$8,273.10
in general payments reported to CMS, 2019-2025
21 companies · $891 in 2025
The $891 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.80 · 2021: $4,345 · 2022: $47.98 · 2023: $237 · 2024: $2,702 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,050 · Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,050.00 |
| Food and Beverage | $1,779.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,461.15 | 2021-2024 | Da Vinci Surgical System |
| Koelis INC. | $2,601.28 | 2024-2025 | |
| Janssen Biotech, INC. | $184.46 | 2024-2025 | Erleada |
| Astrazeneca Pharmaceuticals LP | $152.48 | 2025 | |
| Boston Scientific Corporation | $149.45 | 2019-2025 | Spaceoar System |
| Blue Earth Diagnostics | $131.61 | 2023-2025 | Posluma |
| Medtronic, INC. | $115.06 | 2024 | Interstim |
| Urogen Pharma, INC. | $73.77 | 2023-2025 | Jelmyto |
| Progenics Pharmaceuticals, INC. | $73.17 | 2023 | Pylarify |
| Gilead Sciences, INC. | $47.98 | 2022 | |
| Edap Technomed INC | $43.28 | 2025 | |
| Profound Medical Corp. | $42.54 | 2025 | Tulsa-Pro |
| Merck Sharp & Dohme LLC | $34.41 | 2025 | Welireg, Keytruda |
| Teleflex LLC | $33.34 | 2025 | Barrigel |
| Caris Mpi, INC. | $28.16 | 2025 | Mi Cancer Seek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $24.65 | 2025 | |
| Eisai INC. | $19.34 | 2024 | |
| Mimedx Group, INC. | $17.47 | 2024 | |
| Pfizer INC. | $17.19 | 2025 | |
| Amgen INC. | $11.25 | 2019 | |
| Travere Therapeutics, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Liss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.